Patterns of clinical metastasis in breast cancer: an analysis of 100 patients

Carty, N. J.; Foggitt, AC; Hamilton, C. R.; Royle, G. T.; Taylor, I.

doi:10.1016/s0748-7983(95)95176-8

Cited by 48 publications

(21 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Metastatic carcinoma to this region typically arises from distant spread to a regional lymph node or lymph node group or through bony metastases to the proximal humerus or scapula [15,16]. The proximal humerus and scapula are common sites of metastases for hypernephromas.…”

Section: Discussionmentioning

confidence: 99%

Palliative forequarter amputation for metastatic carcinoma to the shoulder girdle region: Indications, preoperative evaluation, surgical technique, and results

Wittig

Bickels

Kollender

et al. 2001

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Palliative forequarter amputation for metastatic carcinoma to the shoulder girdle region: Indications, preoperative evaluation, surgical technique, and results

Wittig

Bickels

Kollender

et al. 2001

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…1 The majority of the deaths from breast cancer are due to its drug resistance and potential of metastasis to distant organs, such as the lymph nodes, bone, lung, and liver. 2,3 It is well known that an ATP-binding cassette (ABC) family protein plays an important role in drug resistance in multiple malignancies, and its higher expression is proportional to higher resistance towards chemotherapy. Multidrug resistance (MDR) due to high expression of proteins such as P-glycoprotein (P-gp/ABCB1), ABCG2, and BCRP is a major hurdle in breast cancer prognosis and treatment.…”

Section: Introductionmentioning

confidence: 99%

“…2,3 There are several pathways involved in the modulation of breast cancer and its progression to metastasis. [4][5][6] There has been progress made in understanding the biological behavior of estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER-2) for multiple subtypes of breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Drug delivery approaches for breast cancer

Singh

Lillard

et al. 2017

IJN

174

View full text Add to dashboard Cite

Breast cancer is one of the most common cancers affecting women worldwide. The controlled release of drugs to the precise site of the disease using a nanocarrier vehicle increases the therapeutic efficiency of the drugs. Nanotechnology-based approaches used to endorse clinical improvement from a disease also help to understand the interaction of malignant cells with their microenvironment. Receptor-based targeting is another approach for drug delivery which is undergoing clinical trials. Nanoparticles (NPs) delivery has been proven to promise high loading capacity, less toxicity, and stability of the drugs or biomolecules compared to traditional chemotherapeutic drugs. The goal of this review is to present the current problems of breast cancer therapy and discuss the NP-based targeting to overcome the hurdles of conventional drug therapy approach.

show abstract

“…Metastasis to bone is common, particularly with melanoma and carcinomas of the breast, prostate, lung and kidney [1][2][3][4]. Such metastases cause significant morbidity and few therapeutic options are available for their treatment.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of osteolytic bone metastasis by unfractionated heparin

Yee

Butcher

Zeadin

et al. 2008

Clin Exp Metastasis

View full text Add to dashboard Cite

In the current study, we examine heparin's anti-metastatic properties by using a well-defined mouse model of osteolytic bone metastasis. C57BL/6 mice were treated with increasing doses of unfractionated heparin (15, 20, or 25 units/mouse) 30 min prior to the left ventricular injection of GFP-transfected B16F10 melanoma cells. Heparin's effect on tumour burden and bone strength was then quantified 14 days later by bone histomorphometry and biomechanical testing, respectively. Based on histomorphometric analysis of the femurs, injection of GFP-transfected melanoma cells resulted in a 37% decrease in cancellous bone volume and a 68% increase in osteoclast surface. This was associated with a 13% reduction in bone strength as measured by biomechanical testing. However, when the mice were first pre-treated with 25 units of heparin, tumour burden was decreased by 73% and tumour cell-dependent decreases in both cancellous bone volume and bone strength were prevented. Based on these observations, we conclude that heparin inhibits the ability of tumour cells to metastasize to bone and that as such, prevents tumour cell-induced decreases in bone strength.

show abstract

Patterns of clinical metastasis in breast cancer: an analysis of 100 patients

Cited by 48 publications

References 9 publications

Palliative forequarter amputation for metastatic carcinoma to the shoulder girdle region: Indications, preoperative evaluation, surgical technique, and results

Palliative forequarter amputation for metastatic carcinoma to the shoulder girdle region: Indications, preoperative evaluation, surgical technique, and results

Drug delivery approaches for breast cancer

Inhibition of osteolytic bone metastasis by unfractionated heparin

Contact Info

Product

Resources

About